NADH is responsible for the increase in the production of neurotransmitters (happiness hormones) and adrenaline (a hormone responsible for mood and immunity in stressful situations). NADH guarantees the generation of energy and the proper functioning of tissues and organs.
NADH participates in the synthesis of neurotransmitters, serotonin and norepinephrine, which improve well-being, and most importantly, the appropriate psychophysical condition. NADH is responsible for the transformation of arginine alpha-ketoglutarate into nitric oxide, which prevents muscle breakdown, improves physical performance, increases exercise tolerance and facilitates oxygen transport.
The largest cluster of neurons is found in the substantia nigra in the midbrain, which is part of the extrapyramidal nervous system. It is responsible for triggering free movements and regulating the tone of skeletal muscles.
Patients with disorders of this component of the nervous system complain of pathological changes in muscle tone (stiffness in parkinsonism, decreased tension in chorea), the occurrence of involuntary movements (resting tremor in parkinsonism, choreic, athetotic, ballistic, dystonic movements) and difficulties in coordination of movements .
As Dr. George Birkmayer, director of the Parkinson’s Therapy Institute in Vienna, which has been researching NADH for over 30 years, explains, “one third of all the energy we produce in our body is used by our brain. For this reason, an energy deficiency first appears in the brain with symptoms such as a lack of concentration and alertness or mental fog. With more NADH, brain cells perform better (…) Another mechanism by which NADH affects cognition is by stimulating the production of adrenaline. Both of these substances are essential for our cognitive functioning and our memory ”
Interview: Dr. George Birkmayer on NADH for Energy, Healthy Immune Function and More, “ProHealth.”, January 30, 2006.
In 2004, a randomized, double-blind, placebo-controlled clinical trial was conducted to examine the efficacy of NADH in the treatment of Alzheimer’s disease. 24 patients with probable Alzheimer’s disease received 10 mg orally of NADH or placebo. As noted after six months, participants treated with NADH showed no signs of progressive cognitive decline, on the contrary, they showed significantly higher performance scores than the placebo group for verbal fluency and visual-constructive ability, and a tendency to perform better in abstract reasoning. verbal. The researchers concluded: “In line with previous research, the current findings support NADH as a treatment for Alzheimer’s disease.”
Demarin V., Podobnik S.S., Storga-Tomic D., Kay G., Treatment of Alzheimer’s disease with stabilized oral nicotinamide adenine dinucleotide: A randomized, double-blind study, “Drugs Exp Clin Res.” 2004; 30 (1): 27-33.